Stufano Angela, Buonvino Nicola, Trombetta Claudia Maria, Pontrelli Daniela, Marchi Serena, Lobefaro Giuseppe, De Benedictis Leonarda, Lorusso Eleonora, Carofiglio Maria Teresa, Vasinioti Violetta Iris, Montomoli Emanuele, Decaro Nicola, Lovreglio Piero
Section of Occupational Medicine, Interdisciplinary Department of Medicine, University of Bari, 70124 Bari, Italy.
U.O.C. Penitentiary Medicine, Department of Territorial Care, Bari Local Health Authority, 70124 Bari, Italy.
Vaccines (Basel). 2022 Jul 17;10(7):1137. doi: 10.3390/vaccines10071137.
Background. The recent spread of the highly mutated SARS-CoV-2 Omicron variant (B.1.1.529) has raised concerns about protection against COVID-19 in congregate settings such as prisons, characterized by a high risk of transmission and possible difficulties in obtaining adequate vaccination coverage. The present study aims to investigate the spread of an outbreak of COVID-19 in an Italian correctional facility during the dominant circulation of the Omicron BA.1 variant, and also considers BNT162b2 mRNA vaccination coverage among inmates. A COVID-19 screening campaign by RT-PCR was performed on 515 detainees from 4−30 January 2022, in response to an outbreak that began in the correctional facility. Furthermore, 101 serum samples collected from healthy inmates 21 days after having received the second dose of the BNT162b2 vaccine were tested for neutralizing antibodies against both the wild-type SARS-CoV-2 strain and the Omicron BA.1 variant. The global attack rate during the study period was 43.6% (RR 0.8), progressively reducing from unvaccinated inmates (62.7%, RR 1.8) to those who had one dose (52.3%, RR 1.5), two doses (full cycle) (45.0%, RR 1.3), and the third dose (booster) vaccinated group (31.4%, RR 0.7). The percentage of SARS-CoV-2 positive subjects among unvaccinated inmates was significantly higher than in the other groups (p < 0.001), while no significant difference was observed between inmates with one or two vaccine doses. Only two of the positive inmates were hospitalized for COVID-19. The geometric mean titer of neutralizing antibodies in the tested sub-group after two doses of vaccine was lower than in previous studies against the wild-type virus, and showed a complete lack of neutralization against the Omicron variant in 92.1% of individuals. The findings support the need to prioritize vaccination in correctional facilities, as a public health measure to increase the protection of inmates and consequently of prison workers and the community against COVID-19, in coordination with the other prevention strategies.
背景。最近高度变异的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种(B.1.1.529)的传播引发了人们对在监狱等聚集场所预防新型冠状病毒肺炎(COVID-19)的担忧,这些场所的特点是传播风险高,且在获得足够的疫苗接种覆盖率方面可能存在困难。本研究旨在调查在奥密克戎BA.1变种占主导传播期间,意大利一所惩教设施内COVID-19疫情的传播情况,并考虑囚犯中BNT162b2信使核糖核酸(mRNA)疫苗的接种覆盖率。为应对惩教设施内开始的疫情,于2022年1月4日至30日对515名被拘留者开展了逆转录聚合酶链反应(RT-PCR)COVID-19筛查活动。此外,对101份在健康囚犯接种第二剂BNT162b2疫苗21天后采集的血清样本进行了检测,以检测针对野生型SARS-CoV-2毒株和奥密克戎BA.1变种的中和抗体。研究期间的总体感染率为43.6%(相对危险度0.8),从未接种疫苗的囚犯(62.7%,相对危险度1.8)到接种一剂疫苗的囚犯(52.3%,相对危险度1.5)、接种两剂疫苗(完整接种周期)的囚犯(45.0%,相对危险度1.3)以及接种第三剂疫苗(加强针)的囚犯组(31.4%,相对危险度0.7),感染率逐渐降低。未接种疫苗的囚犯中SARS-CoV-2阳性受试者的百分比显著高于其他组(p<0.001),而接种一剂或两剂疫苗的囚犯之间未观察到显著差异。只有两名阳性囚犯因COVID-19住院。两剂疫苗接种后,受试亚组中中和抗体的几何平均滴度低于先前针对野生型病毒的研究,并且在92.1%的个体中显示对奥密克戎变种完全没有中和作用。这些发现支持在惩教设施中优先进行疫苗接种的必要性,作为一项公共卫生措施,与其他预防策略协调,以增强对囚犯的保护,进而保护监狱工作人员和社区免受COVID-19的侵害。